Cellular signature explains why some prostate tumors resist standard treatments

A new study by University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup